Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

NovaSom completes $35M equity financing led by Safeguard Scientifics

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for Obstructive Sleep Apnea (OSA) management, today announced it has closed $35 million in equity financing.

27 Jun 2011

Multiple abstracts on QNEXA long-term clinical study to be presented at ADA 2011

VIVUS, Inc. today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association (ADA) meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA.

22 Jun 2011

VIVUS Avanafil phase 3 trial on erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that the positive results from REVIVE-RP, a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C.

17 Jun 2011

Rotech commences $283.5 million registered exchange offer

Rotech Healthcare Inc., one of the largest providers of home medical equipment and related products and services, announced today that it has commenced a registered exchange offer to exchange up to $283.5 million aggregate principal amount of its Senior Second Lien Notes due 2018 which have been registered under the Securities Act of 1933, as amended for an equal principal amount of its outstanding Senior Second Lien Notes due 2018, which were issued in a private placement.

15 Jun 2011

Guidelines for pediatric use of polysomnography for sleep-disordered breathing before tonsillectomy

A multidisciplinary clinical practice guideline, "Polysomnography for Sleep-Disordered Breathing Prior to Tonsillectomy in Children" will be published as a supplement to the July issue of Otolaryngology-Head and Neck Surgery.

15 Jun 2011

Untreated obstructive sleep apnea can reduce work productivity

Large corporations could save millions of dollars in lost productivity by screening and treating high-risk employees for obstructive sleep apnea, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.

14 Jun 2011

Severe sleep apnea increases risk of gestational diabetes and preterm birth in pregnant women

Sleep apnea is associated with an increased risk of adverse pregnancy outcomes, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS).

13 Jun 2011

Inspire's Stimulation Therapy for Apnea Reduction trial reaches milestones

Inspire Medical Systems, the leading developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today The STAR trial, evaluating both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy, is currently underway at 9 leading medical centers across the United States and at 4 sites in Europe.

10 Jun 2011

School children with bullying behavior more likely to have sleep-disordered breathing

Children who are bullies or have conduct problems at school, are more likely to be sleepy during the day according to University of Michigan Medical School researchers.

1 Jun 2011

Avanafil phase 3 trial in ED following radical prostatectomy meets primary endpoints

VIVUS, Inc. today announced positive results from a phase 3, placebo-controlled clinical trial of the investigational drug avanafil for the treatment of erectile dysfunction in patients following a radical prostatectomy.

25 May 2011

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

A new study links the intermittent interruption of breathing that occurs in patients with obstructive sleep apnea to enhanced proliferation of melanoma cancer cells and increased tumor growth in mice, according to researchers in Spain.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Adenotonsillectomy prevents high blood pressure and heart damage in children with OSA

Removing enlarged tonsils and adenoids may help prevent high blood pressure and heart damage in children who suffer from obstructive sleep apnea, according to a study conducted at Cincinnati Children's Hospital Medical Center.

17 May 2011

Continuous positive airway pressure can increase alertness, improve quality of life in OSA patients

Continuous positive airway pressure, or CPAP, can increase alertness and even improve quality of life for sufferers of obstructive sleep apnea, even if their symptoms are minimal, according to a study conducted by researchers in Europe.

16 May 2011

Continuous positive airway pressure reduces cardiovascular mortality in elderly OSA patients

Continuous positive airway pressure (CPAP) effectively decreases the risk of cardiovascular death in elderly patients who suffer from obstructive sleep apnea (OSA), according to a study conducted by researchers in Spain.

16 May 2011

ImThera Medical concludes Phase I and II protocols for aura6000 European Pilot study in OSA

ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.

9 May 2011

Obstructive Sleep Apnea News and Research

Further Reading